Psychosocial Syndemics are Additively Associated with Worse ART Adherence in HIV-Infected Individuals

AIDS and Behavior

Volumn 19, Issue 6, 2015, Pages 981-986

  Blashill, Aaron J ^a,b,c,g   Bedoya, C Andres ^a,b   Mayer, Kenneth H ^b,c,d,e   O’Cleirigh, Conall ^a,b,c   Pinkston, Megan M ^f,h   Remmert, Jocelyn E ^a   Mimiaga, Matthew J ^c,d   Safren, Steven A ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c FENWAY INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BROWN UNIVERSITY   (United States)

^g One Bowdoin Square ^*  (United States)

^h MIRIAM HOSPITAL   (United States)

Author keywords

Adherence; Antiretroviral therapy; ART; Comorbidity; HIV; Syndemics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; COMORBIDITY; CROSS-SECTIONAL STUDY; DEPRESSION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; MALE; MEDICATION COMPLIANCE; MENTAL STRESS; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; SELF REPORT; SOCIAL SUPPORT; STATISTICS AND NUMERICAL DATA; VIOLENCE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; CROSS-SECTIONAL STUDIES; DEPRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SELF REPORT; SOCIAL SUPPORT; STRESS, PSYCHOLOGICAL; SURVEYS AND QUESTIONNAIRES; VIOLENCE; VIRAL LOAD;

EID: 84931560633     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-014-0925-6     Document Type: Article

References (32)

1. Blashill AJ, Perry N, Safren SA. Mental health: a focus on stress, coping, and mental illness as it relates to treatment retention, adherence, and other health outcomes. Curr HIV/AIDS Rep. 2011;8:215–22.
2. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.
3. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58:181–7.
4. Gonzalez A, Barinas J, O’Cleirigh C. Substance use: impact on adherence and HIV medical treatment. Curr HIV/AIDS Rep. 2011;8:223–34.
5. Parsons JT, Rosof E, Mustanski B. The temporal relationship between alcohol consumption and HIV-medication adherence: a multilevel model of direct and moderating effects. Health Psychol. 2008;27:628–37.
6. Mugavero MJ, Raper JL, Reif S, Whetten K, Leserman J, Thielman NM, et al. Overload: impact of incident stressful events on antiretroviral medication adherence and virologic failure in a longitudinal, multisite human immunodeficiency virus cohort study. Psychosom Med. 2009;71:920–6.
7. Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-social context. Med Anthropol Q. 2003;17:423–41.
8. Stall R, Mills TC, Williamson J, Hart T, Greenwood G, Paul J, et al. Association of co-occurring psychosocial health problems and increased vulnerability to HIV/AIDS among urban men who have sex with men. Am J Public Health. 2003;93:939–42.
9. Safren SA, Blashill AJ, O’Cleirigh CM. Promoting the sexual health of MSM in the context of comorbid mental health problems. AIDS Behav. 2011;15(Suppl 1):S30–4.
10. Safren SA, Reisner SL, Herrick A, Mimiaga MJ, Stall RD. Mental health and HIV risk in men who have sex with men. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S74–7.
11. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann. Intern. Med. 2012;156:817–833, W–284, W–285, W–286, W–287, W–288, W–289, W–290, W–291, W–292, W–293, W–294.
12. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.
13. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968–77.
14. Liu H, Miller LG, Hays RD, Wagner G, Golin CE, Hu W, et al. A practical method to calibrate self-reported adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S104–12.
15. Llabre MM, Weaver KE, Durán RE, Antoni MH, McPherson-Baker S, Schneiderman N. A measurement model of medication adherence to highly active antiretroviral therapy and its relation to viral load in HIV-positive adults. AIDS Patient Care STDS. 2006;20:701–11.
16. Applebaum AJ, Reilly LC, Gonzalez JS, Richardson MA, Leveroni CL, Safren SA. The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients. AIDS Patient Care STDS. 2009;23:455–62.
17. Safren SA, O’Cleirigh C, Tan JY, Raminani SR, Reilly LC, Otto MW, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28:1–10.
18. Safren SA, O’Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80:404–15.
19. Gill CJ, Sabin LL, Hamer DH, Keyi X, Jianbo Z, Li T, et al. Importance of dose timing to achieving undetectable viral loads. AIDS Behav. 2010;14:785–93.
20. Bangsberg DR. Less than 95 % adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–41.
21. Parienti J-J, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008;3:e2783.
22. Amorim P, Lecrubier Y, Weiller E, Hergueta T, Sheehan D. DSM-IH-R psychotic disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI. Eur Psychiatry. 1998;13:26–34.
23. Lecrubier Y, Sheehan D, Weiller E, Amonrim P, Bonora I, Harnett Sheehan K, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997;12:224–31.
24. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33 quiz 34–57.
25. Sheehan D, Lecrubier Y, Harnett Sheehan K, Janavs J, Weiller E, Keskiner A, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry. 1997;12:232–41.
26. Leserman J, Li Z, Drossman DA, Toomey TC, Nachman G, Glogau L. Impact of sexual and physical abuse dimensions on health status: development of an abuse severity measure. Psychosom Med. 1997;59:152–60.
27. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800.
28. Mimiaga M, O’Cleirigh C, Biello K, Robertson A, Safren S, Coates T, et al. The effect of psychosocial syndemic production on 4-year HIV incidence and risk behavior ain a large cohort of sexually active men who have sex with men. J Acquir Immune Defic Syndr. (in press).
29. Nafisseh Soroudi GKP. CBT for medication adherence and depression (CBT-AD) in HIV-infected patients receiving methadone maintenance therapy. Cogn Behav Pract. 2008;15(1):93–106.
30. Allen LB, McHugh RK, Barlow DH. Emotional disorders: a unified protocol. In: Barlow DH, editor. Clinical handbook of psychological disorders. 4th ed. New York: Guilford Press; 2008. p. 216–49.
31. Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety and panic (2nd edition). New York: Guilford Press; 2004.
32. Farchione TJ, Fairholme CP, Ellard KK, Boisseau CL, Thompson-Hollands J, Carl JR, et al. Unified protocol for transdiagnostic treatment of emotional disorders: a randomized controlled trial. Behav Ther. 2012;43:666–78.